Showing results (1-10 of 166) with videos related to
Sort By:
Pageof 17
Expert Opinion on Pharmacotherapy|June 30, 2006
Bortezomib for multiple myelomaRakesh Popat, Simon Joel, Heather Oakervee, et al.British Journal of Haematology|February 3, 2009
Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myelomaRakesh Popat, Heather Oakervee, Catherine Williams, et al.Leukemia & Lymphoma|October 6, 2007
Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftmentHeather Oakervee, Rakesh Popat, Jamie D CavenaghThe Lancet. Haematology|November 16, 2016
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trialRakesh Popat, Sarah R Brown, Louise Flanagan, et al.British Journal of Haematology|February 13, 2009
Patterns of recruitment into acute myeloid leukaemia (AML) 15 and outcome for young patients with AML at a single referral centreJane M Stevens, Finlay Macdougall, Michael Jenner, et al.British Journal of Haematology|April 7, 2009
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myelomaSagar Lonial, Jamie CavenaghClinical Medicine (London, England)|June 3, 2015
Malignant causes of fever of unknown originVanessa Foggo, Jamie CavenaghCancer Cell International|June 3, 2005
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyMario Boccadoro, Gareth Morgan, Jamie CavenaghBMJ Case Reports|April 18, 2017
Long-term stabilisation of myeloma with curcuminAbbas Zaidi, Maggie Lai, Jamie CavenaghBlood|January 8, 2010
Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fractionDavid C Taussig, Jacques Vargaftig, Farideh Miraki-Moud, et al.Pageof 17